Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.

ABSTRACT:

Background

The SARS-CoV-2 omicron (B.1.1.529) variant, which was first identified in November, 2021, spread rapidly in many countries, with a spike protein highly diverged from previously known variants, and raised concerns that this variant might evade neutralising antibody responses. We therefore aimed to characterise the sensitivity of the omicron variant to neutralisation.

Methods

For this cross-sectional study, we cloned the sequence encoding the omicron spike protein from a diagnostic sample to establish an omicron pseudotyped virus neutralisation assay. We quantified the neutralising antibody ID₅₀ (the reciprocal dilution that produces 50% inhibition) against the omicron spike protein, and the fold-change in ID₅₀ relative to the spike of wild-typ

SUBMITTER: Sheward DJ 

PROVIDER: S-EPMC8930016 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature